Copyright. "It is much more important to know what sort of a patient has a disease than what sort of a disease a patient has.
|
|
- Lynn Strickland
- 5 years ago
- Views:
Transcription
1 154 UNIVERSITÁ DEGLI STUDI DI VERONA FACOLTÁ DI MEDICINA E CHIRURGIA Dipartimento di Medicina Sezione di Dermatologia e Venereologia AZIENDA OSPEDALIERA UIVERSITARIA INTEGRATA DI VERONA Unità Operativa di Dermatologia Comorbidities, Systemic nature of disease metabolic & cardiovascular impact Paolo Gisondi The «moisaicism» of treatment success Content flow Patient centered medicine Patient s satisfaction Achievement of treatment goalsin the context of comorbidities Fingerprint of psoriasis Screen and management of comorbidities A. Gaudì "It is much more important to know what sort of a patient has a disease than what sort of a disease a patient has. OslerW
2 157..The growingdemands for quality and safety in health care have refocused attentionon patientoutcomes, even if efforts to ensure more consistently positive outcomes sometimesreduce the physician s prized autonomy The fingerprint of psoriasis I.B.D. Comorbidities Gisondi P et al. J Hepatol 29;51:758-64; Gisondi P et al. Br J Dermatol27;157:68-73; Gisondi P et al. Eur J Dermatol 25;15:279-83; Esposito M. Dermatology 26;212:123-7; De Simone C et al. G Ital Dermatol Venereol 213;148: Skin Liver Rheumatic involvement Metabolic syndrome Depression/anxiety Phenotype of a patient with psoriasis and metabolic syndrome Co-morbidity Treatment Arterial hypertension Ramipril and hydrochlorothiazide Type II diabetes Insulin Hypercholesterolemia, hypertriglyceridemia Statin Obesity - COPD - Liver steatosis - Picture courtesy of Dr Gisondi. 53
3 Increased prevalence of metabolic syndrome in patients with psoriasis 16 Cases Controls P No Sex, M/F 16/178 15/184.8 Age at enrollment; year, mean ± SD 62.1 ± ± BMI, mean ± SD 27.7 ± ± Smoker, n (%) 121 (36.2) 72 (21.).1 Metabolic syndrome, n (%) 12 (3.1) 69 (2.6).5 Waist circumference >12 cm (M) or >88 (F), n (%) 193 (57.1) 159 (47.6).1 Triglyceridemia >1.7 mmol/l, n (%) 128 (37.8) 78 (23.3).1 HDL cholesterol <1. mmol/l (M) or <1.3 (F), n (%) 61 (18.) 72 (21.5).2 Blood pressure >135/85 mm Hg, n (%) 138 (4.8) 132 (39.5).7 Fasting plasma glucose >6.1 mmol/l, n (%) 65 (19.2) 7 (2.9).6 According to the National Cholesterol Education Programme s Adult Treatment Panel III (ATP III), 21. Gisondi P, et al. Br J Dermatol. 27;157: Meta-analysis of the prevalence of MetSin patients with psoriasis Study Sommer 26 Gisondi 27 Chen 28 Chen 29 Al-Mutairi 21 Augustin 21 Bongiorno 21 Nisa 21 Takahashi 21 Love 211 Mebazaa 211 Langan 212 Overall Year of publication NOTE: Weights are from random effects analysis Pooled odds ratio was 2.26 (95% CI: ) Dose response relationship between psoriasis severity and prevalence of MetS Armstrong AW, et al. J Am Acad Dermatol 213 (Epubahead of print) OR (95% CI) 4.22 (2.6, 8.65) 6.86 % weight 1.65 (1.16, 2.35) (.31, 2.27) (.67, 8.59) (2.16, 3.36) (2.21, 3.71) (2.22, 5.21) (2.84, 13.6) (.99, 3.5) (1.2, 3.77) (1.6, 2.82) (1.31, 1.51) (1.7, 3.1) 1. Non-alcoholic fatty liver disease (NAFLD) is associated with the metabolic syndrome Normal liver Pure steatosis Cirrhosis (HCC) Adams LA et al. CMAJ. 25;172: Angulo P. New Eng J Med. 22;346: Steatohepatitis (NASH) Inflammation Fibrosis 54
4 NAFLD is more frequent in patients with psoriasis than in BMI-matched controls NAFLD prevalence (%) % 25% NAFLD prevalence (%) Controls PASI <1 PASI 1 Controls P Gisondi P, et al. J Hepatol. 29;51: Number Sex (M/F) 89/41 18/8 NS Age 51± ±8 NS BMI (kg/m 2 ) 27.5± ±3.2 NS Metabolic syndrome 28% 26% Nutrient overload activates inflammatory responses in adipose tissue, liver, skeletal muscle, pancreas and the hypothalamus, contributing to systemic insulin resistance and glucose intolerance OsbornO et al. Nat Med. 212;18(3): Is inflammation only in the skin in patients psoriasis? with Obesityleads to systemic inflammation 55
5 is associated with an increased serum CRP ± 7.9 CRP levels (mg/l) ± 2.4 Controls patients Gisondi P, et al. Int J Immunopathol Pharmacol.21;23(4): ; Strober B. et al. Br J Dermatol 28;159(2):322 3; Isha J. et al. Indian J Clin Biochem. 211;26(3):39 11; Sergeant A. et al. Br J Dermatol 28;158(2):417 9; Ohtsuka T. et al. Br J Dermatol 28;158(5): Patients with psoriasis and NAFLD have higher IL-6 and lower adiponectin serum levels Serum IL-6 and adiponectin were measured in 21 patients with NAFLD and 22 patients without NAFLD, respectively IL-6 (ng/ml) with NAFLD Gisondi P, et al. J Hepatol. 29;51: p=.2 without NAFLD Adiponectin (µg/ml) with NAFLD p=.3 without NAFLD Adipokines and CRP are increased in psoriasis patients (n=4) than in age-, sex- and BMImatched controls Chemerin (ng/ml) p<.1 p<.1 4 Controls Resistin (ng/ml) Controls p<.3 NS 1 CRP (ng/ml) Visfatin (ng/ml) Controls Controls Gisondi P et al. Br J Dermatol. 212; [Epub ahead of print] 56
6 Systemic and Vascular Inflammation in Patients With Moderate to Severe as Measured by [18F]-FluorodeoxyglucosePositron Emission Tomography Computed Tomography (FDG-PET/CT) 169 FDG-PET/CT identified numerous foci of inflammation in 6 patients with psoriasis within the skin, liver, joints, tendons, and aorta. These findings persisted after adjustment for traditional cardiovascular risk factors in multivariate Mehta NN et al. Arch Dermatol211;147: Inflammatory mediators released from psoriatic lesions may have systemic effects Homocysteine CRP fibrinogen From Paolo Gisondi, Verona (Italy) Liver Endothelial dysfunction TNF-α, INF-α, INF-γ, IL-1, IL-6, IL-17 Adipose tissue Chemerin leptin resistin adiponectin TG LDL HDL Skeletal muscle Insulin resistance glucose Atherosclerosis Pulse Wave Velocity (carotid femoral) was significantly higher in patients with psoriasis than in controls Difference was still significant after adjustment for age, gender, smoking status, hypertension and body mass index 57
7 172 The psoriatic march Cardiovascular diseases Metabolic syndrome Diabetes Genes Environmental triggers Obesity NAFLD Hypertension Dyslipidaemia Smoking Psoriatic arthritis GisondiP, et al. SeminThrombHaemost29;35(3): Gisondi P, et al. Actas Dermosifiliogr 29;1(Suppl. 2):14 21 Framingham risk estimation of developing hard CHD (myocardial infarction and cardiac death) and stroke in patients with psoriasis and controls patients Controls P value Number (male/female) 234 (134/1) 144 (78/66).5 Age, mean ±SD 54.9 ± ± Smokers, n (%) 98 (41) 32 (22).6 BMI, mean ± SD 26.4 ± ± Hypertension, n (%) 18 (46) 22 (15). Systolic blood pressure, mean ± SD 131 ± ± 13.6 Diabetes, n (%) 42 (17) 9 (6).1 Total cholesterol 26 ± ± 35. HDL cholesterol 55 ± 1 61 ± 13. Framingham 5-year estimate, mean ± SD 5.3 ± ± 3.1 Framingham 1-year estimate, mean ± SD 11.2 ± ± 6.1 PASI, mean ± SD (range 1.2 4) 9.9 ± 7.9 BSA, mean ±SD (range 1) 23.2 ±31.3 duration, mean ± SD 17.6 ± 13.6 Framingham risk factors; BMI, body mass index; BSA, body surface area; CHD, coronary heart disease. Gisondi P, et al. Am J Cardiol 21;16: Framingham estimate of risk for hard coronary heart disease and stroke: increased in psoriasis patients 5 years Framingham 5-y estimate Year Risk Framingham 1-y estimate Year Risk Age range Age range Control P <.1 Gisondi P, et al. Am J Cardiol. 21;16:
8 175 is associated with increased cardiovascular mortality Increased risk for cardiovascular mortality in patients hospitalized for psoriasis Risk higher in young patients 1 Severe psoriasis is associated with increased risk of death Patients die years younger than patients without psoriasis 2 Severe psoriasis is associated with an increased risk of cardiovascular death (HR 1.57; 95%CI ) and is independent of traditional CV risk factors 3,4 Severe psoriasis (and PsA) is associated with an increased risk of cardiovascular mortality (RR 1.58; 95%CI ) and is independent of traditional CV risk factors 5 1. Mallbris L, et al. Eur J Epidemiol 24;19:225 3; 2. Gelfand J, et al. Arch Dermatol 27;143:1493 9; 3. Abuabara K, et al. Br J Dermatol 21;163:586 92; 4. Mehta NN, et al. Eur Heart J 21;31:1 6; 5. Ahlehoff O, et al. J Intern Med 211 Why psoriasis is associated to metabolic comorbidities? Wedo not know Common genetic background Enviromental factors By chance Why psoriasis is associated to metabolic comorbidities? Systemic effects of chronic inflammation 1 Insulin resistance 2 Unhealthy lifestyle 3 Common genetic background 4 1. Roifman I, et al. Can J Cardiol 211;27: Ucak S, et al. J Eur Acad Dermatol Venereol26; 2(5): EmreS, et al. J Eur Acad Dermatol Venereol212(Epubahead of print) 4. Suarez-Farinas M, et al. J Invest Dermatol 212;132:
9 178 Mounting evidence Changing clinical practice Screen and Manage comorbidities Boehncke WH Nature 212;492:S55 and obesity: a two-compartment model of inflammation DavidoviciBB, et al. J Invest Dermatol 21;13: therapy in obese patients GG High BMI is associated with a reduced short-term clinical response to all systemic treatments 1. Obesity is associated with reduced long-term retention of all systemic treatments for psoriasis 2. Biologicalswith a fixed-dose regimen (etanercept, adalimumab, alefacept, ustekinumab) may have compromised efficacy in heavier individuals 3,4. Obesity increases the risk of liver and renal toxicity to methotrexate(mtx) and cyclosporine (CsA), respectively 5,6. Weight loss improves the response of obese patients with psoriasis to low-dose CsAtherapy NaldiL, et al. Dermatology28;217: GisondiP, et al. Clinical Derm213 (In press) 3. Clark L, et al. J Am Acad Dermatol 28;58: PuigL. J Eur Acad Dermatol Venereol211;25: RosembergP, et al. J Hepatol27;46: ThaçiD, et al. Dermatology22;25: GisondiP, et al. Am J ClinNutr28; 88:
10 181 Do systemic treatments for psoriasis affect metabolic parameters? Gisondi P, et al. J Eur Acad Dermatol Venereol. 212 Feb 7. [Epub ahead of print] 182 New diagnoses of hypertension, diabetes and dyslipidemia initiation of systemic treatment for psoriasis 183 The relative risk of developing hypertension(or 3.31) and diabetes(or 2.88) at week 52 was higher for patients receiving cyclosporine(n=184) Acitretinwas associated with the risk of developing hypercholesterolaemia(or 1.51) and hypertriglyceridemia(or 1.43) Methotrexateand infliximabwere associated with the risk of developing an increase 2 times of AST(OR 2.6 and 1.87) and ALT(OR 2.38 and 1.74) Gisondi P, et al. J Eur Acad Dermatol Venereol. 212 Feb 7. [Epub ahead of print] 61
11 Anti-TNF-alpha drugs increase body weight in patients with psoriasis 184 A relevant increase (4 1 kg) in body weight was observed in about 25% of patients treated with etanercept or infliximab. Gisondi P, et al. J Eur Acad Dermatol Venereol. 28;22(3): patients? 185 Body mass index and Response rate for 75% improvement in psoriasis area and severity index at months 1 and 7. Blacksquares represent infliximab and open squares Gisondi P, et al. Br J Dermatol. 213 Jan 16 ustekinumab. 186 Is weight reduction helpful in the management of psoriasis in obese 62
12 187 Weight loss and treatment response (I) Weightloss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose CsA therapy A randomised, controlled, investigator-blinded, clinical trial investigated: CsA2.5 mg/kg/day plus low-calorie diet CsA 2.5 mg/kg/day alone Diet regimen Carbohydrates 6% Lipids 25% Proteins 15% Moderate physical activity ( 4 min x4/w) Monthly controls BMI (kg/m 2 ) Females (kcal/day) Males (kcal/day) GisondiP, et al. Am J ClinNutr28;88: Weight loss and treatment response (II) Body weight (kg; mean ± SD) Study to investigate whether moderate weight loss increases the therapeutic response to low (suboptimal)-dose CsA in obese patients with moderate-to-severe chronic plaque psoriasis Months Mean (±SD) reductions in body weight Intervention group: 7. ±3.5 kg Control group:.2 ±.9 kg GisondiP, et al. Am J ClinNutr28;88: p<.1 (Cochran-Mantel-Haenszelanalysis) PASI (mean ±SD) Months CsA2.5 mg/kg/day + calorie-controlled diet CsA2.5 mg/kg/day p<.1 (Cochran-Mantel-Haenszelanalysis) 188 Are there any adverse effects of systemic drugs on the components of metabolic syndrome? 189 MTX CSA Retinoids Anti-TNF-α Ustekinumab Dyslipidemia + + Hypertension + Abdominal obesity Diabetes/reduced glucose tolerance + Liver steatosis + Decreased renal function - + No adverse effects Occasionally significant adverse effects Adverseeffects From Paolo Gisondi, Verona (Italy) 63
13 19 Summary -associated immune responses and inflammation, when protracted and severe enough, may have systemic consequences Therapy of psoriasis is influenced by and may affect other organ systems and co-morbid diseases Patients with severe psoriasis are candidate for early cardiovascular risk factor modification including diet and physical exercise UNIVERSITÁ DEGLI STUDI DI VERONA Dipartimento di Medicina Sezione di Dermatologia e Venereologia Expert considerations in selecting therapies for patients with moderate to severe psoriasis Giampiero Girolomoni University of Verona REGIONE DEL VENETO A.O.U.I. Verona U.O. du Clinica Dermatologica IPC psoriasis preceptorship Verona, 13 June 213 Treatment of Moderate-to-Severe is a life-long disease requiring long-term treatment Patients with moderate-to-severe disease may require phototherapy or systemic therapy + Topical Therapy MTX ADA CSA ETN RET FAE INF PHOTO UST Moderate-to-Severe Plaque Conventional Systemic Therapy Biologic Systemic Therapy Despite a multitude of treatment options, many patients do not receive optimal treatment Adapted from Nast A, et al. J Dtsch Dermatol Ges. 212;1(suppl 2):S1 S95. ADA: adalimumab; CSA: cyclosporine; ETN: etanercept; FAE: fumaric acid ester; INF: infliximab; MTX: methotrexate; PHOTO: phototherapy; RET: retinoids; UST: ustekinumab. 64
Psoriasi e rischio CV
Psoriasi e rischio CV Claudio Borghi Dipartimento di Scienze Mediche e Chirurgiche Università di Bologna David Plunkert 5 Biggest Heart Risks for Men Plos Med, 2006 Sequenza di eventi che causano malattie
More information3/20/2011. Body Mass Index (kg/[m 2 ]) Age at Issue (*BMI > 30, or ~ 30 lbs overweight for 5 4 woman) Mokdad A.H.
U.S. Adults: 1988 Nineteen states with 10-14% 14% Prevalence of Obesity (*BMI > 30, or ~ 30 lbs overweight for 5 4 woman) Metabolic John P. Cello, MD Professor of Medicine and Surgery, University of California,
More informationJ. Gelfand 1, A. Joshi 2, D. Shin 1, A. Dey 2, D. Torigian 1, D. Rader 1, M. Playford 2, M. Ahlman 2, A. Alavi 1, N. Mehta 2.
A Trial to Determine the Effect of Psoriasis Treatment (Adalimumab, Phototherapy, and placebo) on Cardiometabolic Disease: The Vascular Inflammation in Psoriasis (VIP) Trial Abstract 393 J. Gelfand 1,
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationThe Natural History of Psoriasis and Treatment Goals
The Natural History of Psoriasis and Treatment Goals Psoriasis Epidemiology Prevalence Affects 2 3% of adult population (>7 million in US) Caucasians: 25% 2.5% African Americans: 1.3% (more likely to have
More informationPsoriasis: Therapeutic goals
Psoriasis: Therapeutic goals I want to die 50 45 impetiginization infliximab 600 40 35 30 400 25 20 15 200 10 5 0 22-ene 21-feb 23-mar 22-abr 22- may Efalizumab 6 doses: flare + REBOUND CSA 3 21-jun 21-jul
More informationDepression and Subclinical Vascular Diseases in Psoriasis
Depression and Subclinical Vascular Diseases in Psoriasis Nehal N. Mehta, MD MSCE FAHA Section Chief, Inflammation and Cardiometabolic Diseases National Heart, Lung, and Blood Institute, USA Lasker Clinical
More informationPsoriasiform Dermatitis in Children: Calling in the Troops
Psoriasiform Dermatitis in Children: Calling in the Troops Markus Boos, MD PhD Attending Physician, Dermatology Seattle Children s Hospital Assistant Professor of Pediatrics, University of Washington School
More informationRheumatology journal club October 20, 2017 Presented by: Matthew Stoll MD,PhD,PSCS
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis (Mease et al., 2017) Rheumatology journal club October 20,
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationMetabolic Syndrome Is A Key Determinant Of Coronary Microvascular Function In Patients With Stable Coronary Disease Undergoing PCI
Metabolic Syndrome Is A Key Determinant Of Coronary Microvascular Function In Patients With Stable Coronary Disease Undergoing PCI Narbeh Melikian*, Ajay M Shah*, Martyn R Thomas, Roy Sherwood, Mark T
More informationCVD Prevention, Who to Consider
Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..
More informationMetabolic Syndrome. Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah
Metabolic Syndrome Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah Objectives Be able to outline the pathophysiology of the metabolic syndrome Be able to list diagnostic criteria for
More informationDyslipidemia in women: Who should be treated and how?
Dyslipidemia in women: Who should be treated and how? Lale Tokgozoglu, MD, FACC, FESC Professor of Cardiology Hacettepe University Faculty of Medicine Ankara, Turkey. Cause of Death in Women: European
More informationAssociation between arterial stiffness and cardiovascular risk factors in a pediatric population
+ Association between arterial stiffness and cardiovascular risk factors in a pediatric population Maria Perticone Department of Experimental and Clinical Medicine University Magna Graecia of Catanzaro
More informationThe Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk
Update 2013 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine Denver Health
More informationThe Treatment Toolbox for Severe Pediatric Psoriasis
The Treatment Toolbox for Severe Pediatric Psoriasis Dr. Kim A. Papp, MD, PhD, FRCPC, FAAD K Papp Clinical Research and Probity Medical Research Objectives: Treating severe pediatric psoriasis 1. Challenges
More informationRetention rate of systemic drugs in patients with chronic plaque psoriasis
Original article Retention rate of systemic drugs in patients with chronic plaque psoriasis Paolo Gisondi Gianpaolo Tessari Marco Di Mercurio Micol Del Giglio Giampiero Girolomoni Department of Medicine,
More informationPsoriasis and the metabolic syndrome
Psoriasis and the metabolic syndrome MD, PhD James G. Krueger 1 Inflammation as a foundation of metabolic dysregulation and cardiovascular disease risk Diseases of systemic immune activation and inflammation,
More informationThe Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationThe Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk
The Metabolic Syndrome Update 2018 Marc Cornier, M.D. Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine
More informationDiabetes, Diet and SMI: How can we make a difference?
Diabetes, Diet and SMI: How can we make a difference? Dr. Adrian Heald Consultant in Endocrinology and Diabetes Leighton Hospital, Crewe and Macclesfield Research Fellow, Manchester University Relative
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationRONALD PRUSSICK, M.D., FRCPC(C) ASSISTANT CLINICAL PROFESSOR DERMATOLOGY GEORGE WASHINGTON UNIVERSITY WASHINGTON, D.C.
RONALD PRUSSICK, M.D., FRCPC(C) ASSISTANT CLINICAL PROFESSOR DERMATOLOGY GEORGE WASHINGTON UNIVERSITY WASHINGTON, D.C. AbbVie Celgene Immunotec Janssen LEO Pharma L Oreal/Medicis/Galderma Novartis Pfizer
More informationObesity and psoriasis: body weight and body mass index influence the response to biological treatment
DOI: 10.1111/j.1468-3083.2011.04065.x JEADV REVIEW ARTICLE Obesity and psoriasis: body weight and body mass index influence the response to biological treatment L. Puig* Department of Dermatology, Hospital
More informationCardiovascular disease and diabetes Vascular harmony
Cardiovascular disease and diabetes 2018 Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics
More informationNon alcoholic fatty liver disease and atherosclerosis Raul Santos, MD
Non alcoholic fatty liver disease and atherosclerosis Raul Santos, MD Sao Paulo Medical School Hospital Sao Paulo, Brazil Disclosure Honoraria received for consult and/or speaker : Astra Zeneca, Amgen,
More informationIncorporating Biologics Into Your Practice
Incorporating Biologics Into Your Practice Jeffrey M. Sobell MD Tufts University School of Medicine SkinCare Physicians Ora Clinical Research Disclosure Of Relationships With Industry Amgen AbbVie Celgene
More informationRelationship between psoriasis and non-alcoholic fatty liver disease
Original paper Relationship between psoriasis and non-alcoholic fatty liver disease Krishnasamy Narayanasamy 1, Abarna Devi Sanmarkan 2, Karthick Rajendran 3, Chezhian Annasamy 1, Senthilkumar Ramalingam
More informationMETABOLIC SYNDROME AND HCV: FROM HCV
METABOLIC SYNDROME AND HCV: FROM THEORY TO PRACTICE HCV Steatosis Insulin resistance Arun J Sanyal M.D. Chairman, Div. of Gastroenterology, Hepatology and Nutrition Virginia Commonwealth University Richmond,
More informationUpdate on systemic therapies and emerging treatments How do I choose a systemic agent?
Update on systemic therapies and emerging treatments How do I choose a systemic agent? Amy S. Paller, M.D. Walter J. Hamlin Professor and Chair of Dermatology Professor of Pediatrics Northwestern University
More informationElements of Successful PBS Applications. Barbara Radulski RN. Copyright
Elements of Successful PBS Applications Barbara Radulski RN PBS Requirements April 1 2006 THE RULES PBS Requirements 18 years and over Psoriasis x 6 months Failed to achieve an adequate response to 3 systemic
More informationInflammation, rheumatoid arthritis and cardiovascular disease
Inflammation, rheumatoid arthritis and cardiovascular disease Yvette Meißner, Pharmacoepidemiology, German Rheumatism Research Centre www. chronische-entzuendung.org Outline I. Cardiovascular disease II.
More informationImproving Access to Quality Medical Care Webinar Series
Improving Access to Quality Medical Care Webinar Series Presented by The Arizona Telemedicine Program and the Southwest Telehealth Resource Center 2015 UA Board of Regents Welcome AZ, UT, CO, NM & NV FLEX
More informationTerm-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY
MCC-006 POST GRADUATE DIPLOMA IN CLINICAL CARDIOLOGY (PGDCC) 00269 Term-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY Time : 2 hours Maximum Marks : 60 Note : There will be multiple
More informationFamilial hypercholesterolaemia in children and adolescents
Familial hypercholesterolaemia in children and adolescents Rationale and recommendations for early identification and treatment European Atherosclerosis Society Consensus Panel Slide deck adapted from:
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationLIPID GUIDELINES: 2015
LIPID GUIDELINES: 2015 D P Mikhailidis BSc MSc MD FCPP FCP FRSPH FFPM FRCP FRCPath Academic Head Dept. of Clinical Biochemistry (Vascular Disease Prevention Clinics) Royal Free campus University College
More informationOVERVIEW OF ADVERSE CARDIOVASCULAR EVENTS IN THE BRODALUMAB PSORIASIS STUDIES
OVERVIEW OF ADVERSE CARDIOVASCULAR EVENTS IN THE BRODALUMAB PSORIASIS STUDIES Bruce Strober, 1,2 Lawrence F. Eichenfield, 3 April Armstrong, 4 Alice Gottlieb, 5 Kenneth Gordon, 6 Tina Lin, 7 Radhakrishnan
More informationSerum leptin levels in psoriatic patients with non-alcoholic fatty liver disease
Original Article Serum leptin levels in psoriatic patients with non-alcoholic fatty liver disease Zahra Hallaji, MD 1,2 Vahideh Lajevardi, MD 1,2 Robabeh Abedini, MD 1,2 Amir Soleymani, MD 1 Azadeh Goodarzi,
More informationSupplementary Online Content
Supplementary Online Content Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines
More informationComplications of Diabetes mellitus. Dr Bill Young 16 March 2015
Complications of Diabetes mellitus Dr Bill Young 16 March 2015 Complications of diabetes Multi-organ involvement 2 The extent of diabetes complications At diagnosis as many as 50% of patients may have
More informationAutonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors
Autonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors Carmine Pizzi 1 ; Lamberto Manzoli 2, Stefano Mancini 3 ; Gigliola Bedetti
More informationDiabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology
Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the
More informationLa sindrome metabolica e il suo impatto dopo la guarigione nel paziente HIV/HCV
WORKSHOP HCV: la guarigione e il parallelismo tra risposta virologica sostenuta e outcome clinico Milano, 25 Ottobre 2018 Ospedale San Raffaele IRCCS - Sede Turro La sindrome metabolica e il suo impatto
More informationUse of medical record databases to study psoriasis
Use of medical record databases to study psoriasis Joel M. Gelfand, MD, MSCE Professor of Dermatology and Epidemiology Vice Chair for Clinical Research Medical Director, Clinical Studies Unit Director,
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationDiabetes and Concomitant Cardiovascular Disease: Guideline Recommendations and Future Directions
Diabetes and Concomitant Cardiovascular Disease: Guideline Recommendations and Future Directions Diabetes is one of the largest global health emergencies of 21 st century, with the number of people with
More informationGuidelines on cardiovascular risk assessment and management
European Heart Journal Supplements (2005) 7 (Supplement L), L5 L10 doi:10.1093/eurheartj/sui079 Guidelines on cardiovascular risk assessment and management David A. Wood 1,2 * 1 Cardiovascular Medicine
More informationKnow Your Number Aggregate Report Single Analysis Compared to National Averages
Know Your Number Aggregate Report Single Analysis Compared to National s Client: Study Population: 2242 Population: 3,000 Date Range: 04/20/07-08/08/07 Version of Report: V6.2 Page 2 Study Population Demographics
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationMetabolic syn and CVD. Dr : dehestani Imam reza hospital
Metabolic syn and CVD { Dr : dehestani Imam reza hospital Global Distribution of CVDs as Causes of Death, WHO 2011 Worldwide Mortality from Ischemic Heart Disease and Cerebrovascular Disease 2011 Ischemic
More informationRisk Factors for Heart Disease
Risk Factors for Heart Disease Risk Factors we cannot change (Age, Gender, Family History) Risk Factors we can change (modifiable) Smoking Blood pressure Cholesterol Diabetes Inactivity Overweight Stress
More informationPsoriasis in Jordan: a single center experience
Psoriasis in Jordan: a single center experience Shefaa Almashagbeh MD *, Deifallah Alsharari MD *, Hayat Khasawneh MD *, Diana Aljammal * MD, Hamzeh Al-housamieh MD* ABSTRACT Objectives: To evaluate the
More informationPresence of selected metabolic syndrome components in patients with psoriasis vulgaris
Original paper Presence of selected metabolic syndrome components in patients with psoriasis vulgaris Sebastian Uczniak, Zofia A. Gerlicz, Magdalena Kozłowska, Andrzej Kaszuba Department of Dermatology,
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationAt Least 1 in 5 Patients in Your Practice Have Fatty Liver
At Least 1 in 5 Patients in Your Practice Have Fatty Liver What Can You Tell Your Patients Magnus McLeod MD FRCPC Assistant Professor Dalhousie University 30-NOV-2017 NAFLD Non-Alcoholic Fatty Liver Disease
More informationCorrelation of novel cardiac marker
Correlation of novel cardiac marker and mortality in EGAT population. Soluble ST2 hscrp Poh Chanyavanich, MD SukitYamwong, MD Piyamitr Sritara, MD Ramathibodi hospital Background hscrp - the most widely
More informationHSN301 REVISION NOTES TOPIC 1 METABOLIC SYNDROME
HSN301 REVISION NOTES TOPIC 1 METABOLIC SYNDROME What does the term Metabolic Syndrome describe? Metabolic syndrome describes a cluster of cardio-metabolic conditions that increase one's risk of developing
More informationCombination Nonbiologic Therapy in Psoriasis. Sushil Tahiliani, MBBS, MD
Combination Nonbiologic Therapy in Psoriasis Sushil Tahiliani, MBBS, MD Agenda Rationale Preferred and less preferred combination Morphology-specific preferred combinations Doses used in combinations Potential
More informationFrequency of Dyslipidemia and IHD in IGT Patients
Frequency of Dyslipidemia and IHD in IGT Patients *Islam MS, 1 Hossain MZ, 2 Talukder SK, 3 Elahi MM, 4 Mondal RN 5 Impaired glucose tolerance (IGT) is often associated with macrovascular complications.
More informationBackground. Metabolic syndrome T2DM CARDIOVASCULAR DISEASE. Major Unmet Clinical Need. Novel Risk Factors. Classical Risk Factors LDL-C.
The effect of metabolic syndrome for left ventricular geometry, arterial stiffness and carotid intima-media thickness in Korean general population Result from Atherosclerosis RIsk of Rural Area in Korea
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationMetabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine
Metabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine Setting the scene GB, 43 yo AA man followed for hypothyroidism returns on LT4 125 mcg/d and has a TSH=1.1
More informationPIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia
PIEDMONT ACCESS TO HEALTH SERVICES, INC. Policy Number: 01-09-021 SUBJECT: Guidelines for Screening and Management of Dyslipidemia EFFECTIVE DATE: 04/2008 REVIEWED/REVISED: 04/12/10, 03/17/2011, 4/10/2012,
More informationThe Metabolic Syndrome Prof. Jean-Pierre Després
The Metabolic Syndrome 1 Jean-Pierre Després, Ph.D., FAHA, FIAS Quebec Heart and Lung Institute Department of Medicine Université Laval Québec, Canada Reaven s syndrome X Triglycerides HDL cholesterol
More informationClinical Trial Synopsis TL-OPI-518, NCT#
Clinical Trial Synopsis, NCT# 00225264 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl vs Glimepiride
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationEffective Interventions in the Clinical Setting: Engaging and Empowering Patients. Michael J. Bloch, M.D. Doina Kulick, M.D.
Effective Interventions in the Clinical Setting: Engaging and Empowering Patients Michael J. Bloch, M.D. Doina Kulick, M.D. UNIVERSITY OF NEVADA SCHOOL of MEDICINE Sept. 8, 2011 Reality check: What could
More informationAndrejs Kalvelis 1, MD, PhD, Inga Stukena 2, MD, Guntis Bahs 3 MD, PhD & Aivars Lejnieks 4, MD, PhD ABSTRACT INTRODUCTION. Riga Stradins University
CARDIOVASCULAR RISK FACTORS ORIGINAL ARTICLE Do We Correctly Assess the Risk of Cardiovascular Disease? Characteristics of Risk Factors for Cardiovascular Disease Depending on the Sex and Age of Patients
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationASSeSSing the risk of fatal cardiovascular disease
ASSeSSing the risk of fatal cardiovascular disease «Systematic Cerebrovascular and coronary Risk Evaluation» think total vascular risk Assess the risk Set the targets Act to get to goal revised; aupril
More informationProven and Proposed Cardiovascular Benefits of Soyfoods
Proven and Proposed Cardiovascular Benefits of Soyfoods Mark Messina, PhD, MS Soy Nutrition Institute Loma Linda University Nutrition Matters, Inc. markjohnmessina@gmail.com Alpro Foundation 20 years symposium
More informationPATIENTS AND METHODS:
BACKGROUND: Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease characterized by erosive synovitis that involves peripheral joints and implicates an important influence in the quality
More informationDyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram
Dyslipidaemia Is there any new information? Dr. A.R.M. Saifuddin Ekram PhD,FACP,FCPS(Medicine) Professor(c.c.) & Head Department of Medicine Rajshahi Medical College Rajshahi-6000 New features of ATP III
More informationHypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents
Hypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents Stella Stabouli Ass. Professor Pediatrics 1 st Department of Pediatrics Hippocratio Hospital Evaluation of
More informationTHE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS
THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS Hormonal regulation INSULIN lipid synthesis, lipolysis CORTISOL lipolysis GLUCAGON lipolysis GROWTH HORMONE lipolysis CATECHOLAMINES lipolysis LEPTIN catabolism
More informationCVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic
CVD Risk Assessment Michal Vrablík Charles University, Prague Czech Republic What is Risk? A cumulative probability of an event, usually expressed as percentage e.g.: 5 CV events in 00 pts = 5% risk This
More informationEstablished Risk Factors for Coronary Heart Disease (CHD)
Getting Patients to Make Small Lifestyle Changes That Result in SIGNIFICANT Improvements in Health - Prevention of Diabetes and Obesity for Better Health Maureen E. Mays, MD, MS, FACC Director ~ Portland
More informationAccelerated atherosclerosis begins years prior to the diagnosis of diabetes
Joslin Diabetes Forum 211: Optimizing Care for the Practicing Clinician Risk for atherosclerosis is 2 4 times greater in patients with diabetes CVD accounts for 65% of diabetic mortality >5% of patients
More informationThe promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease
The promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease Steve Smith, Group Director Scientific Affairs, Diabetes & Metabolism GlaxoSmithKline R & D
More informationMetabolically healthy obesity and NAFLD
News & Views Metabolically healthy obesity and NAFLD Giovanni Targher and Christopher D. Byrne Giovanni Targher is at the Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University
More informationPrevalence of metabolic syndrome in psoriasis vulgaris: a cross sectional study from a tertiary care hospital of South-East Rajasthan
International Journal of Research in Dermatology http://www.ijord.com Research Article DOI: http://dx.doi.org/10.18203/issn.2455-4529.intjresdermatol20162832 Prevalence of metabolic syndrome in psoriasis
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationMOLINA HEALTHCARE OF CALIFORNIA
MOLINA HEALTHCARE OF CALIFORNIA HIGH BLOOD CHOLESTEROL IN ADULTS GUIDELINE Molina Healthcare of California has adopted the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel
More informationSupplementary Appendix
Supplementary Appendix Increased Risk of Atrial Fibrillation and Thromboembolism in Patients with Severe Psoriasis: a Nationwide Population-based Study Tae-Min Rhee, MD 1, Ji Hyun Lee, MD 2, Eue-Keun Choi,
More informationCentral pressures and prediction of cardiovascular events in erectile dysfunction patients
Central pressures and prediction of cardiovascular events in erectile dysfunction patients N. Ioakeimidis, K. Rokkas, A. Angelis, Z. Kratiras, M. Abdelrasoul, C. Georgakopoulos, D. Terentes-Printzios,
More informationMetabolic Syndrome in Asians
Metabolic Syndrome in Asians Alka Kanaya, MD Asst. Professor of Medicine, UCSF Asian CV Symposium, November 17, 2007 The Metabolic Syndrome Also known as: Syndrome X Insulin Resistance Syndrome The Deadly
More informationsurtout qui n est PAS à risque?
3*25 min et surtout qui n est PAS à risque? 2018 ESC/ESH Hypertension Guidelines 2018 ESC-ESH Guidelines for the Management of Arterial Hypertension 28 th ESH Meeting on Hypertension and Cardiovascular
More informationA hospital based study to assess the prevalence of cardiovascular risk factors among patients of chronic plaque psoriasis
International Journal of Research in Medical Sciences Bhat B et al. Int J Res Med Sci. 2016 Nov;4(11):4974-4978 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Original Research Article DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20163801
More informationMetabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk
Metabolic Syndrome Update 21 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes University of Colorado Denver Denver Health Medical Center The Metabolic
More informationPatient access to therapy Dr Lluís Puig
Department of Dermatology Hospital de la Santa Creu i Sant Pau IPC NOVARTIS PSORIASIS PRECEPTORSHIP Patient access to therapy Dr Lluís Puig Barcelona, July 9th-10th, 2013 MSD Symposium The Overweight Pa7ent:
More informationAssessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution
CLINICAL Viewpoint Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients Copyright Not for Sale or Commercial Distribution By Ruth McPherson, MD, PhD, FRCPC Unauthorised
More informationPlasma fibrinogen level, BMI and lipid profile in type 2 diabetes mellitus with hypertension
World Journal of Pharmaceutical Sciences ISSN (Print): 2321-3310; ISSN (Online): 2321-3086 Published by Atom and Cell Publishers All Rights Reserved Available online at: http://www.wjpsonline.org/ Original
More informationPsoriasis management. A/Prof Amanda Oakley Dermatologist, Waikato
Psoriasis management A/Prof Amanda Oakley Dermatologist, Waikato AbbVie Breakfast Session, 14 June 2014 Disclosure This breakfast session is sponsored by Abbvie Autoimmune skin disorders Psoriasis Eczema
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More information(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects
Table 1. Distribution of baseline characteristics across tertiles of OPG adjusted for age and sex (n=6279). Continuous variables are reported as mean with 95% confidence interval and categorical values
More information